| Literature DB >> 30356649 |
Sarah Hurtado-Bagès1,2, Iva Guberovic1,3, Marcus Buschbeck1,4.
Abstract
The exchange of replication-coupled canonical histones by histone variants endows chromatin with specific features. The replacement of the canonical H2A histone for the histone variant macroH2A is one of the most remarkable epigenetic modifications. The three vertebrate macroH2A proteins have a unique tripartite structure consisting of H2A-like domain, unstructured linker, and macrodomain. Macrodomains are ancient globular folds that are able to bind nicotinamide adenine dinucleotide (NAD+) derived metabolites. Here, we will briefly describe the physiological relevance of the metabolite binding in the context of chromatin. In particular, we will focus on the macroH2A1.1 isoform that binds ADP-ribose and poly-ADP-ribose polymerase 1 (PARP1) enzyme, a cellular stress sensor. We will discuss the impact of this interaction in the context of cancer, senescence, cell stress and energy metabolism.Entities:
Keywords: PARP1; epigenetic; macroH2A1.1; metabolism; stress response
Year: 2018 PMID: 30356649 PMCID: PMC6189284 DOI: 10.3389/fgene.2018.00417
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Impact of macroH2A1.1-PARP1 axis on metabolic phenotypes.
| Model system | Metabolic phenotype | Reference | ||||||
|---|---|---|---|---|---|---|---|---|
| Mice strain or cell line | Gender | Age (weeks) | Experimental manipulation | Description | Outcome | |||
| MacroH2A1 | Loss or gain of function | C57BL/6 mice | Mainly Male | From 1 to 8 | MacroH2A1 KO | Fertile and viable, develop glucose intolerance. Deregulation of genes involved in liver metabolism during new born-adult transition. | Negative | |
| 129Vx C57BL/6 mice | Female | From 6 to 12 | MacroH2A1 KO | 50% exacerbated liver steatosis. | Negative | |||
| 129Vx C57BL/6 mice | Mainly Male | From 1 to 8 | MacroH2A1 double KO | Smaller with reduced lean body mass. | Negative | |||
| 129Vx C57BL/6 mice | Male | From 12 to 24 | MacroH2A1 KO | Fat mass reduction and protected against HFD-induced obesity. | Positive | |||
| C57BL/6 | Male | From 6 to 18 | MacroH2A1.2 gain of function | Increased leaness, glucose tolerance, decrease fat accumulation in the liver and pancreas. | Positive | |||
| human HepG2 hepatocytes cell line | Male-derived | / | MacroH2A1.2 overexpression | Activation of lipogenic genes, enhanced lipid uptake, and triglycerides. | Negative | |||
| human HepG2 hepatocytes cell line | Male-derived | / | MacroH2A1.1 overexpression | Protected against lipid accumulation with reduction of triglycerides. | Positive | |||
| human HepG2 and murine Hepa1-6 cell line | Male-derived | / | MacroH2A1.1 overexpression | Protected hepatocytes against lipid accumulation. | Positive | |||
| murine 3T3-L1 adipocytes cell line | Male-derived | / | MacroH2A1.1 downregulation (shRNAs) | Adipogenesis abrogation via EZH2 interaction and regulation of Wnt signaling. | Positive | |||
| murine C2C12 myotubes cell line | Female-derived | / | MacroH2A1.1 downregulation (siRNAs) | Altered mitochondrial activity, mitochondrial NAD+ and NMN depletion. | Negative | |||
| PARP1 | Loss or gain of function | C57BL/6 mice | Male | From 0 to 46 | PARP1 KO | Lower body weight gain with HFD. | Positive | |
| C57BL/6 mice | Male | From 0 to 13 | PARP1 KO | Increased of hepatic steatosis. | Negative | |||
| C57BL/6 mice | Male | From 4 to 46 | PARP1 KO | Increased of mitochondrial biogenesis and NAD+ content via SIRT1 activity. | Positive | |||
| C57BL/6 mice | Not indicated | Not indicated | PARP1 KO | Altered circadian rhythms and food intake. | Negative | |||
| C57B1/6 mice | Not indicated | Not indicated | Ectopic integration of human PARP1 | Premature development of inflammation and age-associated pathologies. Gain weight and glucose intolerance. | Negative | |||
| PARP1 | Loss or gain of function | 129/SvlmJ mice 129VxC57BL/6 mice | Mainly male | From 4 to 19 | PARP1 KO | Gain weight; and increased susceptibility to high-fat diet-induced obesity. Hyperglycemia, hyperinsulinemia, increase of plasma leptin levels. | Negative | |
| Increase of fat mass and decrease of lean mass. | ||||||||
| 129Vx C57BL/6 mice | Not indicated | From 4 to 10 | PARP1 KO | Protection against streptozotocin diabetes. | Positive | |||
| 129Vx C57BL/6 mice | Not indicated | 20 | PARP1 KO | Protection against | Positive | |||
| mice (unclear from Jackson laboratory) | Male | From 4 to 48 | PARP1 KO | Prevented drastic decrease of β-cell proliferation during aging. | Positive | |||
| human HEK293T kidney cells | Female-derived | / | PARP1 KO | Enhanced mitochondrial gene expression and respiration. | Positive | |||
| murine 3T3-L1 adipocytes | Male-derived | / | PARP1 KO | Reduced adipocyte differentiation and PPARy-dependent gene expression. | Positive | |||
| murine C2C12 | Male-derived | / | PARP1 KO | Increase of adipogenic transcriptional program through C/EBPβ PARylation. | Negative | |||
| murine C2C12 myotubes cell line | Female-derived | / | PARP1 siRNA | Increased oxidative phosphorylation and glycolytic activity. | Positive | |||
| PARP1 | Inhibition | C57BL/6 mice | Male | From 4 to 46 | Inhibition (PJ34) | Better lipid metabolic profile, increase of NAD+ level in Brown adipose tissue and skeletal muscle. | Positive | |
| C57BL/6 mice | Not indicated | 20 | Inhibition (PJ34) | Enhanced mitochondrial biogenesis in Chagas mice with myocardial fibrosis. | Positive | |||
| C57BL/6 mice | Male | From 10 to 28 | Inhibition (MRL-45696) | Enhanced mitochondrial content and activity in Brown adipose tissue and skeletal muscle. | Positive | |||
| 129Vx C57BL/6 mice | Not indicated | Not indicated | Inhibition (nicotinamide) | Prevented pancreatic β-cell destruction. | Positive | |||
| Wistar rat | Male | Not indicated | Inhibition (nicotinamide, or 3-ABA) | Improved β-cell regeneration and prevents diabetes mellitus. | Positive | |||
| diabetic db/db(Leprdb/db) mice | Male | 5 | Inhibition (lNO1001; PJ34) | Prevented diabetes induces podocytes and blocks their hyperglycemia. | Positive | |||
| murine C2C12 myotubes cell line | Female-derived | / | Inhibition (PJ34) | Better mitochondrial activity and enhanced oxidative metabolism. | Positive | |||